13 terminated. 13 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Terminated 13 |
| Phase 2 | 5 | Terminated 5 |
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Terminated | University of Washington | 1 | 2024-12-18 | 2025-07-29 |
| Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma Descartes-15 - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 4 | 2024-06-19 | 2025-11-24 |
| A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab - Multiple Myeloma, Relapsed Cancer | Phase 1 | Terminated | Anaveon AG | 4 | 2023-02-10 | 2024-02-12 |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib - Plasmacytoma, Recurrent Multiple Myeloma | Phase 1 | Terminated | National Cancer Institute (NCI) | 35 | 2018-06-14 | 2026-02-10 |
| Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma ACTR087, SEA-BCMA - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Terminated | Cogent Biosciences, Inc. | 15 | 2018-02-22 | 2020-03-30 |
| Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma Cabozantinib - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | University of Nebraska | 11 | 2018-02-21 | 2023-09-08 |
| A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma Lintuzumab AC 225 - Refractory Multiple Myeloma | Phase 1 | Terminated | Actinium Pharmaceuticals | 2 | 2016-12-01 | 2022-03-08 |
| Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 1 | Terminated | Case Comprehensive Cancer Center | 8 | 2013-10-07 | 2017-02-17 |
| Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, bortezomib - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 1 / Phase 2 | Terminated | University of Washington | 31 | 2008-11-01 | 2017-09-08 |
| Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma obatoclax mesylate, bortezomib, laboratory biomarker analysis - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 11 | 2008-07-01 | 2015-01-12 |
| A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma Noscapine HCl - Refractory Multiple Myeloma | Phase 1 | Terminated | Cougar Biotechnology, Inc. | 12 | 2007-12-01 | 2016-10-07 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma alvocidib - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 46 | 2005-12-01 | 2016-08-08 |
| Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma bortezomib, tipifarnib, laboratory biomarker analysis - Refractory Multiple Myeloma, Stage II Multiple Myeloma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 64 | 2005-08-01 | 2013-10-08 |
Multiple Myeloma (13) · Recurrence (3) · Disease (1) · Hematologic Diseases (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1)
Blood Protein Disorders (13) · Cardiovascular Diseases (13) · Hemic and Lymphatic Diseases (13) · Hemorrhagic Disorders (13) · Hemostatic Disorders (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphoproliferative Disorders (13) · Neoplasms by Histologic Type (13) · Paraproteinemias (13) · Vascular Diseases (13) · Hematologic Diseases (12) · Neoplasms (12) · Neoplasms, Plasma Cell (12) · Disease Attributes (4)
Bortezomib (4) · Dexamethasone (4) · Lenalidomide (3) · Biopsy (2) · Calcium Dobesilate (2) · carfilzomib (2) · 2-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1) · Cyclophosphamide (1) · Cyclosporine (1) · Mycophenolic Acid (1) · Noscapine (1) · Specimen Handling (1) · Whole-Body Irradiation (1) · alvocidib (1) · auricularum (1)
National Cancer Institute (NCI) (4) · University of Washington (2) · Actinium Pharmaceuticals (1) · Anaveon AG (1) · Cartesian Therapeutics (1) · Case Comprehensive Cancer Center (1) · Cogent Biosciences, Inc. (1) · Cougar Biotechnology, Inc. (1) · University of Nebraska (1)
United States (12) · Denmark (1) · France (1) · Germany (1) · Spain (1) · Switzerland (1)
Alexander Stewart (1) · Avinash Desai, MD (1) · Darrin Beaupre (1) · Eduard Gasal, MD (1) · Hans C Lee (1) · Hien K Liu, MD (1) · Jeffrey Jones (1) · Jessica Sachs, MD (1) · Muhamed Baljevic, MD (1) · Pamela Becker (1) · Rahul Banerjee, MD (1)
N01CM00070 (1), N01CM62203 (1), N01CM62205 (1), N01CM62208 (1), P30CA016058 (1), P30CA043703 (1), R01CA083978 (1), U01CA076576 (1), UM1CA186688 (1)